Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) generates frequent news flow around its work in hereditary angioedema (HAE) and the commercialization of EKTERLY (sebetralstat). Company press releases highlight regulatory approvals, commercial launches, clinical data presentations and financial updates tied to this first and only oral on-demand treatment for acute HAE attacks in people 12 years of age and older.
News items cover major milestones such as FDA approval of EKTERLY in the United States, subsequent approvals in the European Union, United Kingdom, Switzerland, Australia, Singapore and Japan, and the initiation of commercial launches in the U.S. and Germany. KalVista also reports on licensing and commercialization agreements with partners like Kaken Pharmaceutical in Japan, Pendopharm in Canada and Multicare Pharmaceuticals in Latin America, which expand EKTERLY’s reach into additional markets.
Investors and clinicians following KALV can track updates on net product revenue from EKTERLY, patient start forms, prescriber activation and refill trends, as well as financing events such as the issuance of convertible senior notes. The company regularly announces new clinical and real‑world data from the KONFIDENT, KONFIDENT‑S and KONFIDENT‑KID studies, including patient satisfaction, pediatric interim results and European experience with sebetralstat, often presented at meetings such as the American College of Allergy, Asthma & Immunology Annual Scientific Meeting and the German Allergy Congress.
Additional KalVista news includes corporate governance developments, board and executive appointments, inducement equity grants and participation in healthcare investor conferences. This news page allows readers to follow how KalVista advances EKTERLY globally, engages with the HAE community and reports on its operational and financial progress over time.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the grant of inducement options for 23,000 shares to four new employees on January 3, 2022. The options have an exercise price of $13.91 per share, matching the closing stock price on the grant date. One-fourth of the options will vest after one year, with the remaining vesting monthly over three years, contingent on continued employment. This issuance follows Nasdaq Listing Rule 5635(c)(4), designed to incentivize new hires as KalVista continues its focus on developing therapies for unmet medical needs.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has provided an operational update alongside its financial results for the second fiscal quarter ended October 31, 2021. The company is initiating a Phase 3 clinical trial for KVD900 and enrolling patients in the KVD824 Phase 2 KOMPLETE trial. Significant progress includes the confirmation of trial designs by the FDA and positive Phase 2 results for KVD900. However, the company reported a net loss of $19.7 million, with no revenue generated during the quarter, and increased R&D and G&A expenses.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the grant of inducement options for 18,000 shares to six newly-hired employees, effective December 1, 2021. The options have an exercise price of $13.63 per share, aligned with the closing stock price on the grant date. Vesting occurs over four years: one-fourth after one year, with remaining shares vesting monthly over three years. This move complies with Nasdaq Listing Rule 5635(c)(4) and is part of KalVista's strategy to attract talent for its innovative therapies targeting hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals (NASDAQ: KALV) has completed a positive End-of-Phase 2 meeting with the FDA regarding its clinical trial for KVD900, an oral treatment for hereditary angioedema (HAE). The company expects to initiate its Phase 3 trial in Q1 2022, with positive results from previous trials supporting the trial design. The Phase 3 trial will recruit approximately 100 patients across over 50 sites worldwide, aiming to evaluate symptom relief times, including severe HAE attacks. KalVista is well-capitalized, expected to fund operations until early 2024.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its participation in two upcoming investor conferences:
- Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 9:20 a.m. EST
- Jefferies London Healthcare Conference on November 16, 2021, at 5:40 p.m. GMT
Live webcasts of the presentations will be available on www.kalvista.com, with archives accessible for 30 days post-event. KalVista focuses on small molecule protease inhibitors for unmet medical needs, including therapies for hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) presented Phase 2 data for KVD900 at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. KVD900 is an oral treatment for hereditary angioedema (HAE) that demonstrated rapid absorption, with significant symptom relief observed faster than placebo (1.6 hours vs 9.0 hours, p0.0001). The findings suggest KVD900 could significantly improve patient outcomes during HAE attacks. The data also indicates strong agreement between Patient Global Impression of Change and other reported outcomes, underscoring its clinical relevance.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced that its compensation committee granted inducement options to purchase 23,000 shares of common stock to six newly-hired employees on November 3, 2021. The options have an exercise price of $18.22 per share, equal to the closing price on the grant date. Vesting occurs over four years, with one-fourth vesting on the first anniversary and the rest monthly over three years. KalVista focuses on developing small molecule protease inhibitors for unmet medical needs, specifically targeting HAE and DME.
KalVista Pharmaceuticals (NASDAQ: KALV) announced on October 1, 2021, the grant of inducement options to six newly-hired employees, allowing them to purchase a total of 40,000 shares of common stock at an exercise price of $17.33, which matches the stock's closing price on the grant date. The options will vest over four years, with one-fourth vesting on the one-year anniversary and the remainder vesting monthly thereafter. These grants comply with Nasdaq Listing Rule 5635(c)(4), highlighting KalVista's commitment to incentivizing new talent.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced participation in a fireside chat at the Cantor Virtual Global Healthcare Conference on September 27, 2021, at 8:40 a.m. ET. A live webcast will be accessible on their website, with an audio archive available for 30 days post-event. KalVista focuses on developing small molecule protease inhibitors for unmet medical needs, with significant products like KVD900 for hereditary angioedema (HAE) and KVD001 for diabetic macular edema (DME) in clinical trials.
KalVista Pharmaceuticals (NASDAQ: KALV) has announced the lifting of the clinical hold on its Phase 2 trial for KVD824, intended for the oral prophylactic treatment of hereditary angioedema (HAE). The FDA's approval allows the company to initiate U.S. site activities for the KOMPLETE trial, which aims to enroll 48 patients across 30 sites in 13 countries. Previous studies indicated KVD824 maintained necessary plasma concentrations with no serious adverse events reported. The trial's primary endpoint focuses on the rate of HAE attacks during treatment.